GSK sees positive results from trials of Cervarix and combined migraine drug
UK-based pharmaceutical major GlaxoSmithKline says that its developmental cervical cancer vaccine Cervarix has shown 100% efficacy in the prevention of precancerous lesions associated with human papilloma virus types 16 and 18, which are thought to be responsible for more than 70% of cervical cancer cases.
Cervarix impresses in trials
The findings are from a double-blind study which enrolled 1,113 women between the ages of 15 and 25. During the program, the subjects were randomized to receive either three doses of Cervarix formulated with the AS04 adjuvant or placebo. The results showed that antibodies to HPV 16 and 18 were detected in 98% of the women enrolled in the program for up to 4.5 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze